Close
Retinal conditions like macular degeneration and diabetic eye disease can progress quickly and quietly. At NERSI Eye Care, our board-certified specialist uses Anti-VEGF Injections for Vision Loss Treatment to reduce retinal damage, control fluid buildup, and help protect the vision you have before further loss occurs.
VEGF (vascular endothelial growth factor) is a protein that, when overproduced, triggers abnormal blood vessel growth and leakage inside the retina. Left unchecked, this process causes progressive, often irreversible central vision loss. Anti-VEGF Injections for Vision Loss Treatment work by blocking this protein directly, stopping the damage at its source rather than managing symptoms after the fact.
When VEGF levels become elevated, new and fragile blood vessels form beneath or within the retina. These vessels leak fluid, causing swelling, distortion, and damage to the cells responsible for sharp central vision. Anti-VEGF eye injections intercept this process, reducing swelling, preventing further retinal deterioration, and stabilizing or in many cases improving vision clarity over time.
Retinal injection treatment is delivered as a simple in-office procedure requiring no surgical incision and minimal recovery time, making it one of the most accessible and effective interventions available for serious retinal disease.
Direct Answer Box: Anti-VEGF injections block a protein that triggers abnormal, leaking blood vessels in the retina. By stopping that growth process, they reduce fluid buildup, protect retinal tissue, and help stabilize or improve vision.
Many patients arrive uncertain about what the procedure involves. The process is straightforward, quick, and performed entirely in our clinic without the need for a surgical facility.
Not every retinal condition responds to the same medication. The most appropriate option for Anti-VEGF treatment for vision loss is selected based on your specific diagnosis, imaging results, and clinical history.
Eylea is one of the most widely used medications in Anti-VEGF Injections for Vision Loss Treatment, indicated for wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion. It works by binding VEGF more broadly, helping reduce retinal swelling and fluid accumulation more completely.
Izervay is specifically designed for geographic atrophy, the advanced form of dry macular degeneration that causes progressive loss of retinal tissue. As a specialized intravitreal injection treatment, it addresses a distinct biological pathway to help slow the rate at which retinal tissue is lost.
Avastin is a widely used off-label Anti-VEGF injection with a long track record of clinical use in retinal disease management. Its effectiveness in reducing abnormal retinal blood vessel growth has been validated through extensive research and real-world clinical application.
When should you consider this type of treatment? The following symptoms can indicate retinal disease that responds to Anti-VEGF Injections for Vision Loss Treatment. Early evaluation is critical because vision lost to retinal damage is often difficult to recover.
Straight lines that appear wavy, bent, or irregular are among the earliest signs of macular disease. This distortion is caused by fluid disrupting the retinal layers responsible for central vision.
Patches where vision is missing, dimmed, or obscured in the center of the visual field can indicate retinal cell damage or fluid accumulation directly affecting the macula.
Because the macula controls fine detail, tasks that depend on central vision, including reading printed text or recognizing faces at close range, become progressively harder as macular conditions advance.
Patients managing diabetes should be especially vigilant. Diabetic retinopathy and diabetic macular edema are among the most common indications for injections for macular degeneration and related retinal conditions, and can progress significantly before symptoms become obvious.
Any sudden or rapid change in vision quality warrants same-day evaluation. NERSI offers same-day emergency appointments for patients experiencing acute changes in vision.
Candidacy for Anti-VEGF Injections for Vision Loss Treatment depends on a confirmed diagnosis and imaging evaluation. The therapy is appropriate for a specific range of retinal conditions rather than applied broadly.
The wet form of AMD involves active blood vessel leakage and responds directly to Anti-VEGF suppression. Izervay offers a targeted Anti-VEGF therapy path for patients with geographic atrophy, helping slow the progression of retinal tissue loss.
Diabetic retinopathy and diabetic macular edema are leading causes of vision loss among adults. Injections for macular degeneration and diabetic retinal disease directly address the leaking vessels driving vision deterioration, making early intervention essential.
When a vein in the retina becomes blocked, fluid backs up and damages surrounding tissue. Retinal injection treatment reduces this fluid accumulation and limits the extent of vision damage caused by the blockage.
Patients noticing gradual or accelerating changes in central vision clarity should not delay evaluation. Progressive retinal conditions worsen more quickly without treatment, and earlier intervention consistently produces better outcomes.
Most patients start with monthly injections over an initial loading phase, then move to a customized schedule based on how their condition responds. This structured approach is central to how Anti-VEGF Injections for Vision Loss Treatment works in practice.
Treatment frequency is not fixed. It varies depending on the specific retinal condition being treated, the medication selected, the severity of disease at diagnosis, and how the eye responds over time. Some patients on intravitreal injection treatment move to injections every two to four months after an initial stabilization period. Others with more active disease require more consistent intervals throughout their treatment course.
At NERSI, treatment timing is guided by regular retinal imaging rather than a predetermined calendar. This means your schedule reflects what your eyes actually need, ensuring optimal outcomes at every stage of care.
Dr. Bajwa's subspecialty training and fellowship background give her a precise clinical foundation for retinal disease. Every patient receiving treatment gets ophthalmologist-level evaluation at each visit, not a technician-led process.
NERSI's diagnostic suite includes OCT (Optical Coherence Tomography), fundus photography, and corneal topography, allowing accurate disease monitoring at every stage of retinal injection treatment so no change goes undetected between appointments.
The choice of medication, injection frequency, and monitoring schedule is tailored to each patient's condition, history, and response. No two retinal cases are managed identically.
The goal at NERSI is not simply to complete a course of Anti-VEGF therapy. It is to protect your functional vision for as long as possible. Every clinical decision is made with that objective in mind.
Many patients are understandably apprehensive about an eye injection for retinal disease. Our team walks you through every step, answers your questions honestly, and ensures the experience is as comfortable as possible.
Dr. Bajwa brings subspecialty precision to every retinal patient she sees at NERSI. Her fellowship training at Yale University and advanced study under Dr. Foster at MERSI in Boston established a clinical foundation that extends well beyond general ophthalmology, including deep experience with retinal disease, Anti-VEGF injection procedures, and ocular inflammatory conditions.
Every patient is seen, evaluated, and treated by the physician directly, not passed through layers of technicians, ensuring that the clinical judgment behind your care is consistent and informed at every visit.
Dr. Asima Bajwa, MD | Board-Certified Ophthalmologist
They are used to treat retinal conditions caused by abnormal blood vessel growth and fluid leakage, including wet macular degeneration, diabetic macular edema, geographic atrophy, and retinal vein occlusion. Anti-VEGF Injections for Vision Loss Treatment are most effective when started before significant retinal damage has occurred.
In many patients, yes. Anti-VEGF eye injections can stabilize vision and prevent further loss. Some patients experience measurable improvement in clarity, particularly when treatment begins early.
The eye is numbed before the procedure. Most patients feel mild pressure rather than pain. Any discomfort is minor and typically short-lived after the appointment.
The injection itself takes only a few seconds. Including preparation and post-procedure observation, most in-office visits are completed in under 30 minutes.
Eylea treats wet AMD, DME, and retinal vein occlusion through broad VEGF suppression. Avastin is a cost-effective off-label alternative with a similar mechanism. Izervay targets geographic atrophy through a distinct biological pathway. The appropriate option is selected based on your diagnosis and imaging results.
Some patients notice stabilization or improvement within weeks of starting Anti-VEGF treatment for vision loss. Others respond more gradually. Regular imaging at follow-up visits allows the plan to be adjusted based on your response.
Medicare and most major insurers cover FDA-approved treatments for qualifying retinal diagnoses. NERSI accepts Aetna, Blue Cross Blue Shield, Cigna, Medicare, and United Healthcare. Contact our office to confirm coverage prior to your visit.
Starting treatment early gives you the best chance of preserving the vision you have. Our team provides precise retinal diagnosis and personalized care for every patient, from first evaluation through every stage of ongoing management.
Same-day emergency appointments available. Monday through Friday, 7:30 AM to 4:00 PM. Located at 44095 Pipeline Plaza, Suite 330, Ashburn, VA 20147.
Please note: To help us stay on schedule and accommodate all patients, new patients who arrive 15 minutes or more after their scheduled appointment may need to be rescheduled. If you are running late, please call our clinic to let us know. Thank you.
Copyright © 2026 Nur Eye Research and Surgery Institute. All rights reserved.
Designed and Marketing By Verbsz Marketing
